These results also highlight that ovarian cancer cell death could be achieved without directly inhibiting Mcl-1 and/or Bcl-xL, which opens new therapeutic perspectives for the management of ovarian cancer. This evidence concerns the gene BCL2L1 and ovarian carcinoma.